[Federal Register Volume 62, Number 138 (Friday, July 18, 1997)]
[Notices]
[Pages 38541-38545]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-18948]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[Program Announcement Number 781]


Cooperative Agreement To Provide Information Concerning the 
Diagnosis, Prevention and Treatment of Viral Hepatitis-Related Liver 
Disease

Introduction

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of funds beginning in fiscal year (FY) 1997 for a 
cooperative agreement program with one or more national organizations 
to develop and distribute materials to educate the general public, 
affected patients, risk groups, physicians, and other health care 
providers about the prevention, diagnosis and medical management of 
acute and chronic liver disease due to all types of viral hepatitis, 
with initial emphasis on hepatitis C.
    CDC is committed to achieving the health promotion and disease 
prevention objectives of ``Healthy People 2000,'' a national activity 
to reduce morbidity and mortality and improve the quality of life. This 
announcement is related to the priority area of Immunization and 
Infectious Diseases. (To order a copy of Healthy People 2000, see WHERE 
TO OBTAIN ADDITIONAL INFORMATION.)

Authority

    This program is authorized under sections 301 (42 U.S.C. 241) and 
317(k)(2) (42 U.S.C. 247b(k)(2)) of the Public Health Service Act, as 
amended.

Smoke-Free Workplace

    CDC strongly encourages all grant recipients to provide a smoke-
free workplace and promote the nonuse of all tobacco products, and 
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in 
certain facilities that receive Federal funds in which education, 
library, day care, health care, and early childhood development 
services are provided to children.

Eligible Applicants

    Eligible applicants are limited to national nonprofit organizations 
which devote a major portion of their activities to educating the 
public, patients, and health care providers about the diagnosis, 
prevention, and medical management of viral hepatitis-related liver 
disease. Eligible applicants must also have established collaboration 
with diverse national organizations and groups that represent health 
care professionals, minority populations, volunteers, consumers, 
patients, community organizations, groups at risk of infection with 
hepatitis viruses, government entities, and others.
    Organizations that meet these eligibility requirements are the most 
appropriate applicants because:
    1. They have the expertise and experience needed to produce 
effective health education materials and messages and develop 
strategies to maximize health care professionals and public awareness 
and education about the risk factors, preventive measures, and 
treatment options for viral hepatitis, including hepatitis C.
    2. They have demonstrated interest in providing accurate, pertinent 
information on viral hepatitis-related liver disease to the public, 
populations at risk of infection, patients, and health care 
professionals.
    3. They have the ability to collaborate with health professional 
schools (medical, dental, public health, nursing, allied health), 
medical and health professional societies, blood banks, health care 
facilities, community organizations, at-risk populations, and local, 
State, and Federal government agencies to increase awareness of how 
viral hepatitis, in general, and hepatitis C virus (HCV) infections 
specifically, can be identified, treated, and prevented.
    4. They can conduct formative research, pilot test potential 
messages and materials, and evaluate their effectiveness in increasing 
knowledge and motivating behavior change.

Availability of Funds

    Approximately $250,000 is available in FY 1997 to fund up to two 
cooperative agreements. It is expected that the awards will begin on or 
about September 1, 1997, for a 12-month budget period within a project 
period of up to three years. Continuation awards within the project 
period will be made on the basis of satisfactory progress and the 
availability of funds. Funding estimates may vary and are subject to 
change.

[[Page 38542]]

Use of Funds

Restrictions on Lobbying

    Applicants should be aware of restrictions on the use of Department 
of Health and Human Services (HHS) funds for lobbying of Federal or 
State legislative bodies. Under the provisions of 31 U.S.C. Section 
1352 (which has been in effect since December 23, 1989), recipients 
(and their subtier contractors) are prohibited from using appropriated 
Federal funds (other than profits from a Federal contract) for lobbying 
Congress or any Federal agency in connection with the award of a 
particular contract, grant, cooperative agreement, or loan. This 
includes grants/cooperative agreements that, in whole or in part, 
involve conferences for which Federal funds cannot be used directly or 
indirectly to encourage participants to lobby or to instruct 
participants on how to lobby.
    In addition, the FY 1997 Departments of Labor, HHS, and Education, 
and Related Agencies Appropriations Act, which became effective October 
1, 1996, expressly prohibits the use of 1997 appropriated funds for 
indirect or ``grass roots'' lobbying efforts that are designed to 
support or defeat legislation pending before State legislatures. 
Section 503 of this new law, as enacted by the Omnibus Consolidated 
Appropriations Act, 1997, Division A, Title I, Section 101(e), Pub. L. 
No. 104-208 (September 30, 1966), provides as follows:

    Sec. 503(a) No part of any appropriation contained in this Act 
shall be used, other than for normal and recognized executive-
legislative relationships, for publicity or propaganda purposes, for 
the preparation, distribution, or use of any kit, pamphlet, booklet, 
publication, radio, television, or video presentation designed to 
support or defeat legislation pending before the Congress, * * * 
except in presentation to the Congress or any State legislative body 
itself.
    (b) No part of any appropriation contained in this Act shall be 
used to pay the salary or expenses of any grant or contract 
recipient, or agent acting for such recipient, related to any 
activity designed to influence legislation or appropriations pending 
before the Congress or any State legislature.

Background

    Hepatitis C virus (HCV) is an important cause of acute and chronic 
hepatitis in the United States. The CDC estimates 30,000 persons were 
infected with HCV in 1995, with most infections occurring among young 
adults with high-risk behaviors or lifestyles. The most efficient mode 
of transmission of HCV is through direct percutaneous exposures, such 
as from sharing of contaminated needles among injection drug users or 
from blood transfusion. Exposures associated with acquiring HCV 
infection include blood transfusion prior to 1990, receipt of clotting 
factor concentrates that were not virally inactivated, injection drug 
use, snorting cocaine, hemodialysis, health care work involving 
frequent exposure to blood (in particular, accidental needle sticks), 
sexual contact with a partner infected with HCV, multiple sex partners 
(heterosexual or homosexual), and birth to a HCV-infected woman. 
Currently, most HCV infections are acquired by high-risk drug use (60 
percent) and sexual behaviors (20 percent). There is no evidence that 
transmission of HCV is associated with commercial use of equipment for 
tattooing, body piercing, hair cutting (razors), or manicures.
    The most important feature of hepatitis C is the high rate of 
progression to chronic infection, even in the absence of active liver 
disease. About 70 percent of HCV infected persons develop chronic 
hepatitis that can progress to cirrhosis and hepatocellular carcinoma, 
with an estimated 8-10,000 HCV-related chronic liver disease deaths 
each year. A national survey conducted in the U.S. from 1988 to 1994 
found that 1.8 percent of a representative sample of the civilian 
population had antibody to HCV, corresponding to 3.9 million HCV-
infected Americans. Infection rates were higher in males than in 
females, and higher in African Americans than in Caucasians. The 
highest rates of HCV infection were found in adults aged 30-49 years.
    Because of the large degree of confusion and lack of accurate 
information about hepatitis C, educational materials are necessary for 
both health care providers and the general public about the risks of 
acquiring HCV infection, indications for serological testing and other 
diagnostic methods, treatment issues, and means to prevent the spread 
of infection. Prevention strategies to identify, treat and counsel 
persons with chronic infection and measures to reduce transmission in 
high-risk groups are needed. For health care providers, these should 
include information on identifying patients with a history of high-risk 
exposures, interpretation of diagnostic test results, discussion of 
treatment options, guidelines for counseling patients, and the 
importance of appropriate disease reporting.
    Hepatitis A virus (HAV) infection is a major cause of acute 
hepatitis in the United States (U.S.). At least 150,000 persons are 
newly infected each year with 75,000 developing clinical illness 
associated with substantial morbidity and medical and work-loss costs. 
Up to 20 percent of persons with hepatitis A are hospitalized with an 
average 27 days of work loss. Direct and indirect costs were estimated 
to be more than $200 million in 1991. Most cases of hepatitis A occur 
by person-to-person transmission in community-wide outbreaks. The 
highest rates of disease occur in children, adolescents and young 
adults, and among American Indians/Alaska Natives and Hispanics. 
Children may be the major reservoir for transmission of HAV; nearly 30 
percent of reported cases occur among children less than 15 years of 
age, and many more children probably have unrecognized or asymptomatic 
infection that is not recognized until transmission to older household 
contacts occurs.
    Hepatitis A vaccines are licensed for persons over two years of 
age, with virtually 100 percent of children, adolescents, and adults 
developing protective levels of antibody after the vaccine series. 
While the most effective means of achieving control of HAV infection 
would be to include routine hepatitis A vaccination in the childhood 
vaccination schedule, the vaccine is not licensed, as yet, for children 
under two years of age. Current recommendations are for pre-exposure 
vaccination of groups at increased risk for HAV infection (e.g., 
persons traveling to countries with high rates of HAV infection, men 
who have sex with men, drug users) and routine vaccination of children 
and adults in communities with high or intermediate rates of HAV 
infection.
    Acute and chronic hepatitis B virus (HBV) infections are a major 
cause of morbidity and mortality in the United States, consuming a 
large amount of health care resources. Approximately 60,000 new 
infections with HBV continue to occur each year in spite of the 
availability of an effective vaccine. The existing pool of 1.25 million 
persons with chronic HBV infection are potentially infectious to others 
and are at risk of long-term sequelae that include chronic active 
hepatitis, cirrhosis and primary hepatocellular carcinoma. 
Approximately 6,000 deaths occur annually from HBV-related chronic 
liver disease. Antiviral therapy is moderately effective in eliminating 
chronic HBV infection. However, most chronically infected persons are 
not being identified, counseled, or treated. Patients with chronic HBV 
infection need to be counseled about treatment options and health care 
interventions that can be used to prevent HBV transmission to others.
    The most effective means of preventing new HBV infections and HBV-
related acute and chronic liver

[[Page 38543]]

disease is by immunizing susceptible persons with hepatitis B vaccine. 
A comprehensive strategy to eliminate HBV transmission in the U.S. has 
been developed and includes prevention of perinatal HBV infection, 
routine vaccination of infants, catch-up vaccination of young children 
at high risk of HBV infection, routine vaccination of adolescents, and 
vaccination of adolescents or adults at high risk of infection. 
Currently, routine maternal screening to prevent perinatal HBV 
infection and routine vaccination of infants and adolescents have been 
widely implemented throughout the U.S. However, high levels of 
vaccination coverage have not been achieved for childhood populations 
at high risk of infection and for adults and adolescents in groups at 
high risk of infection.

Purpose

    The purpose of this cooperative agreement program is to assist 
national organizations in fulfilling their goals of developing and 
disseminating accurate information on viral hepatitis to target 
audiences that include health care providers, at-risk populations, 
patients, and the general public. Specifically, the objectives are to: 
(1) improve health care provider knowledge about the diagnosis, 
prevention, health consequences, and medical management of viral 
hepatitis (with initial emphasis on hepatitis C), and (2) improve 
community, risk group, and patient awareness of the importance of and 
the means for the prevention of viral hepatitis (with initial emphasis 
on hepatitis C) by collecting, developing, and disseminating 
information and educational materials.

Program Requirements

    In conducting activities to achieve the purpose of this program, 
the recipient will be responsible for the activities described under A. 
below, and CDC will be responsible for the activities described under 
B. below:

A. Recipient Activities

    1. Review existing available educational information on the 
diagnosis, prevention, health consequences, and medical management of 
viral hepatitis. Such materials may be available from the recipient and 
others (e.g., nonprofit organizations, pharmaceutical and vaccine 
manufacturers, provider organizations, Federal and State governments, 
etc.). Determine gaps and in information and efforts to effectively 
reach groups targeted by these available materials. For example, review 
the materials for accuracy, completeness, and appropriateness for 
target audiences which include various professional groups (i.e., 
physician, nursing, dental), at-risk groups, and racial/ethnic groups 
with high rates of the various types of viral hepatitis.
    2. Develop and evaluate new educational materials that will fill 
identified gaps through collaboration with organizations and groups 
that represent the target audiences. Use formative research to develop 
various types of health education materials (e.g., fact sheets, 
brochures, pamphlets, videos, public service announcements, letters to 
the editor, posters, articles for the lay press) that will fill the 
identified gaps in health education materials needed for the various 
disease-specific target audiences. Such materials should target both 
the general public and at-risk populations. Messages for at-risk groups 
should be appropriate for the specific diseases (HAV, HBV, HCV) and 
risk groups should include men who have sex with men and injection drug 
users where appropriate. Evaluation of the effectiveness of newly 
developed materials should employ methods such as:
    a. Focus groups and/or intercept interviews with the public and 
specific at-risk populations to determine acceptance and clarity of 
messages.
    b. Pilot testing messages with representative audiences for appeal, 
effectiveness in increasing knowledge, and motivating behavior change.
    3. Evaluate various methods used to disseminate health education 
materials/messages to determine the most effective methods for the 
target audiences.
    4. Disseminate existing and newly developed materials to target 
audiences which include individuals at risk for or infected with HCV, 
health care providers, and the general public. Recipient may network 
with other organizations or groups (professional, voluntary, 
governmental, community-based) that represent minority populations with 
high rates of viral hepatitis or groups/populations at high risk of 
specific types of viral hepatitis, e.g., National Institute for Drug 
Abuse (NIDA), American Social Health Association (ASHA).

B. CDC Activities

    1. Provide scientific and public health consultation and assistance 
in the development of materials and activities related to the 
cooperative agreement.
    2. Provide scientific collaboration for appropriate aspects of the 
activities, including information on disease impact, vaccination 
coverage levels, and prevention strategies.
    3. Assist in reporting and validating relevant information 
concerning viral hepatitis made available to Federal, State, local 
health agencies, health care providers, and volunteer organizations.

Technical Reporting Requirements

    Narrative progress reports are required semiannually. The first 
semiannual report is required with each year's noncompeting 
continuation application and should cover program activities from date 
of the previous report (or date of award for reporting in the first 
year of the project). The second semiannual report is due 90 days after 
the end of each budget period and should cover activities from the date 
of previous report. Progress reports should address the status of all 
recipient activities above, including: (1) A comparison of actual 
accomplishments to the objectives established for the funding period; 
(2) The reasons for failing to meet any established objectives; (3) 
Description and explanation of any modifications of program activities 
and protocols; and (4) Other pertinent information such as key staffing 
changes or reasons for unexpectedly high or low costs for performance.
    An original and two copies of a financial status report are 
required no later than 90 days after the end of each budget period. A 
final performance report and financial status report are due no later 
than 90 days after the end of the project period.
    All reports are submitted to the Grants Management Branch, Centers 
for Disease Control and Prevention (CDC), Attention: Sharron P. Orum, 
Grants Management Officer, Procurement and Grants Office, 255 East 
Paces Ferry Road, NE., Mailstop E-18, Room 300, Atlanta, Georgia 30305.

Application Content

    All applicants must develop their applications in accordance with 
PHS Form 5161-1 (OMB Number 0937-0189) information contained in this 
Program Announcement, and the instructions regarding typing, mailing, 
and format outlined below.

Typing and Mailing

    An original and two copies of the application must be submitted. 
Pages must be clearly numbered, and a complete index to the application 
and its appendixes must be included. Please begin each separate section 
on a new page. The original and each copy of the application must be 
submitted unstapled and unbound. All materials must be typewritten, 
single-spaced, with unreduced type on 8-\1/2\'' by 11'' paper,

[[Page 38544]]

with at least 1'' margins headers and footers, and printed on one side 
only. The application narrative must not exceed 10 single-spaced pages 
(excluding budget and appendices). Unless indicated otherwise, all 
information requested below must appear in the narrative. Materials or 
information that should be part of the narrative will not be accepted 
if placed in the appendices.

Format

    The application narrative must contain the following sections in 
the order presented below:
1. Introduction
    Clearly demonstrate that applicant satisfies the eligibility 
requirements under Eligible Applicants section above. Briefly provide a 
thorough description of the need or problem(s) to be addressed and the 
specific and unique contributions that applicant can make in the 
development and dissemination of health education materials about viral 
hepatitis with initial emphasis on hepatitis C.
2. Capacity and Personnel
    Describe applicant's ability to develop health education materials 
and to conduct education and awareness campaigns for specific 
audiences, including populations at risk for specific types of viral 
hepatitis. Describe applicant's resources, facilities, and professional 
personnel that will be involved in conducting the activities. Include 
in an appendix curriculum vitae for all professional personnel involved 
with the project. Describe plans for administration of the project and 
identify administrative resources/personnel that will be assigned to 
the project. Provide in an appendix letters of support from all key 
participating non-applicant organizations which clearly indicate their 
commitment to participate as described in the operational plan.
3. Objectives and Technical Approach
    Present specific objectives for the proposed project which are 
measurable, time-phased, and clearly address the Purpose and Recipient 
Activities for this program. Present a detailed operational plan for 
initiating and conducting the project which clearly and adequately 
addresses these objectives (if proposing a multi-year project, provide 
a detailed description of first-year activities and a brief overview of 
subsequent-year activities). Clearly identify specific assigned 
responsibilities for all key professional personnel and their time 
commitment. Include a clear description of applicant's technical 
approach/methods which are directly relevant to the above objectives. 
Describe the nature and extent of collaboration with CDC and others 
during various phases of the project. Describe in detail a plan for 
evaluating the effectiveness of newly developed educational materials 
in increasing target audience knowledge and facilitating changes in 
their behavior, including assessing the impact of strategies on 
professional practice behaviors. Describe plans to evaluate overall 
progress toward achieving project objectives.
4. Budget
    Provide a line-item budget and accompanying detailed, line-by-line 
justification that demonstrates the request is consistent with the 
purpose and objectives of this program. If requesting funds for any 
contracts, provide the following information for each proposed 
contract: (1) Name of proposed contractor, (2) breakdown and 
justification for estimated costs, (3) description and scope of 
activities to be performed by contractor, (4) period of performance, 
and (5) method of contractor selection (e.g., sole-source or 
competitive solicitation).
5. Human Subjects
    Whether or not exempt from DHHS regulations, if the proposed 
project involves human subjects, describe (in an appendix) adequate 
procedures for the protection of human subjects. Ensure that women, 
racial, and ethnic minority populations are appropriately represented 
in applications for research involving human subjects (see the section 
OTHER REQUIREMENTS for additional information). A copy of CDC policy is 
included in the application kit.

Evaluation Criteria (Total 100 points)

    Applications will be reviewed and evaluated according to the 
following criteria:

1. Understanding (25 points)

    Extent to which the application responds to the objectives of this 
cooperative agreement program including: (a) Applicant's understanding 
of the objectives of the cooperative agreement, and (b) relevance of 
the applicant's plan to the stated objectives.

2. Capacity (25 points)

    Extent to which applicant describes adequate resources and 
facilities (both technical and administrative) for conducting the 
project. Extent to which applicant documents that professional 
personnel involved in the project are qualified and have past 
experience and achievements related to the proposed activities. Extent 
to which applicant includes letters of support from appropriate non-
applicant organizations, individuals, etc., needed to carry out 
proposed activities and the extent to which such letters clearly 
indicate the author's commitment to participate as described in the 
operational plan.

3. Objectives and Technical Approach (45 points total)

    a. Extent to which applicant describes objectives of the proposed 
project which are consistent with the purpose of this cooperative 
agreement program and which are measurable and time-phased. (15 points)
    b. Extent to which applicant presents a detailed operational plan 
for initiating and conducting the project which clearly and 
appropriately addresses all Recipient Activities. Extent to which 
applicant clearly identifies specific assigned responsibilities and 
time commitment of all key professional personnel. Extent to which the 
plan clearly describes applicant's technical approach/methods for 
conducting the proposed studies and extent to which the approach/
methods are appropriate and adequate to accomplish the objectives. 
Extent to which applicant describes collaboration with CDC and/or 
others during various phases of the project. (15 points)
    c. Extent to which applicant provides a detailed and adequate plan 
for evaluating effectiveness of newly developed educational materials 
in increasing target audience knowledge and facilitating changes in 
their behavior, including assessing the impact of strategies on 
professional practice behaviors. Extent to which applicant describes 
plans to evaluate progress toward achieving project objectives. (15 
points)

4. Budget (not Scored)

    Extent to which the proposed budget is reasonable, clearly 
justifiable, and consistent with the intended use of grant/cooperative 
agreement funds.

5. Human Subjects (5 Points)

    If the proposed project involves human subjects, whether or not 
exempt from the Department of Health and Human Services (DHHS) 
regulations, the extent to which adequate procedures are described for 
the protection of human subjects. Note: Objective Review Group (ORG) 
recommendations on the adequacy of protections include: (1) Protections 
appear adequate and there are no comments to make or concerns to raise, 
(2) protections appear adequate,

[[Page 38545]]

but there are comments regarding the protocol, (3) protections appear 
inadequate and the ORG has concerns related to human subjects, (4) 
disapproval of the application is recommended because the research 
risks are sufficiently serious and protection against the risks are 
inadequate as to make the entire application unacceptable, and (5) 
protections appear adequate that women, racial and ethnic minority 
populations are appropriately represented in applications involving 
human research.

Executive Order 12372 Review

    This program is not subject to the Executive Order 12372 review.

Public Health System Reporting Requirement

    This program is not subject to the Public Health System Reporting 
Requirements.

Catalog of Federal Domestic Assistance Number

    The Catalog of Federal Domestic Assistance number is 92.283.

Other Requirements

Paperwork Reduction Act

    Projects that involve the collection of information from 10 or more 
individuals and funded by the cooperative agreement will be subject to 
review by the Office of Management and Budget (OMB) under the Paperwork 
Reduction Act.

Human Subjects

    If the proposed project involves research on human subjects, the 
applicant must comply with the Department of Health and Human Services 
Regulations, 45 CFR part 46, regarding the protection of human 
subjects. Assurance must be provided to demonstrate that the project 
will be subject to initial and continuing review by an appropriate 
institutional review committee. The applicant will be responsible for 
providing assurance in accordance with the appropriate guidelines and 
form provided in the application kit. Should human subjects review be 
required, the proposed work plan should incorporate time lines for such 
development and review activities.

Women, Racial and Ethnic Minorities

    It is the policy of the Centers for Disease Control and Prevention 
(CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) 
to ensure that individuals of both sexes and the various racial and 
ethnic groups will be included in CDC/ATSDR-supported research projects 
involving human subjects, whenever feasible and appropriate. Racial and 
ethnic groups are those defined in OMB Directive NO. 15 and include 
American Indian, Alaskan Native, Asian, Pacific Islander, Black and 
Hispanic. Applicants shall ensure that women, racial and ethnic 
minority populations are appropriately represented in applications for 
research involving human subjects. Where clear and compelling rationale 
exist that inclusion is inappropriate or not feasible, this situation 
must be explained as part of the application. This policy does not 
apply to research studies when the investigator cannot control the 
race, ethnicity and/or sex of subjects. Further guidance to this policy 
is contained in the Federal Register, Vol. 60, No. 179, pages 47947-
47951, dated Friday, September 15, 1995.

Application Submission and Deadline

    The original and two copies of the application Form PHS-5161-1 (OMB 
Number 0937-0189) must be submitted to Sharron P. Orum, Grants 
Management Officer, Grants Management Branch, Procurement and Grants 
Office, Centers for Disease Control and Prevention (CDC), 255 East 
Paces Ferry Road, NE., Room 305, Mailstop E-18, Atlanta, Georgia 30305, 
on or before August 19, 1997.
    Deadline: Applications shall be considered as meeting the deadline 
if they are either:
    (a) Received on or before the deadline date; or
    (b) Sent on or before the deadline date and received in time for 
submission to the objective review group. (Applicants must request a 
legibly dated U.S. Postal Service postmark or obtain a legibly dated 
receipt from a commercial carrier or U.S. Postal Service. Private 
metered postmarks shall not be acceptable as proof of timely mailing.)
    Late applications: Applications which do not meet the criteria in 
(a) or (b) above are considered late applications. Late applications 
will not be considered and will be returned to the applicant.

Where to Obtain Additional Information

    A complete program description and information on application 
procedures are contained in the application package. Business 
management technical assistance may be obtained from Bernice A. Moore, 
Grants Management Specialist, Grants Management Branch, Procurement and 
Grants Office, Centers for Disease Control and Prevention (CDC), 255 
East Paces Ferry Road, NE., Room 305 Mailstop E-18, Atlanta, Georgia 
30305, telephone (404) 842-6802, fax (404) 842-6513, or Internet or CDC 
WONDER electronic mail at [email protected].
    Programmatic technical assistance may be obtained from Louise S. 
Barden, Health Educator, Hepatitis Branch, National Center for 
Infectious Diseases, Centers for Disease Control and Prevention (CDC), 
1600 Clifton Road, Mailstop G-37, Atlanta, Georgia 30333, telephone 
(404) 639-2709, (fax) 404-639-1538, or Internet or CDC Wonder 
electronic mail [email protected].
    To receive an application kit, please call (404) 332-4561. You will 
be asked to leave your name, mailing address, and telephone number. 
Please reference Announcement Number 781 when requesting information 
and submitting your application. You may also obtain this announcement 
and other CDC announcements from one of two Internet sites: CDC's 
homepage at http://www.cdc.gov or the Government Printing Office 
homepage (including free on-line access to the Federal Register at 
http://www.access.gpo.gov).
    Potential applicants may obtain a copy of Healthy People 2000 (Full 
Report: Stock No. 017-001-00474-0) or Healthy People 2000 (Summary 
Report: Stock No. 017-001-00473-1) referenced in the Introduction 
through the Superintendent of Documents, Government Printing Office, 
Washington, DC 20402-9325, telephone (202) 512-1800.

    Dated: July 14, 1997.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for 
Disease Control and Prevention (CDC).
[FR Doc. 97-18948 Filed 7-17-97; 8:45 am]
BILLING CODE 4163-18-P